The estimated Net Worth of Michael L. Meyers is at least $1.21 Milion dollars as of 30 December 2021. Michael Meyers owns over 5,900 units of Syndax Pharmaceuticals Inc stock worth over $395,089 and over the last 8 years he sold SNDX stock worth over $0. In addition, he makes $818,472 as Senior Vice President a Chief Medical Officer at Syndax Pharmaceuticals Inc.
Michael has made over 4 trades of the Syndax Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,900 units of SNDX stock worth $51,743 on 30 December 2021.
The largest trade he's ever made was exercising 5,900 units of Syndax Pharmaceuticals Inc stock on 30 December 2021 worth over $51,743. On average, Michael trades about 700 units every 105 days since 2017. As of 30 December 2021 he still owns at least 21,566 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Michael Meyers stock trades at the bottom of the page.
Dr. Michael L. Meyers M.D., Ph.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Meyers previously served as our Senior Vice President, Chief Development Officer from August 2015 to April 2016. Prior to joining us, Dr. Meyers held a number of senior roles at Johnson & Johnson, a publicly traded company, serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Dr. Meyers also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc., a privately held life sciences company, predecessor to Sanofi-Aventis U.S. LLC, and worked in oncology clinical development at the Schering-Plough Research Institute. Dr. Meyers served on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He received his M.D. and his Ph.D. in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to the American Osteopathic Association. Dr. Meyers completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.
As the Senior Vice President a Chief Medical Officer of Syndax Pharmaceuticals Inc, the total compensation of Michael Meyers at Syndax Pharmaceuticals Inc is $818,472. There are 4 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.
Michael Meyers is 70, he's been the Senior Vice President a Chief Medical Officer of Syndax Pharmaceuticals Inc since 2016. There are no older and 16 younger executives at Syndax Pharmaceuticals Inc.
Michael's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin a Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include: